Table 4.
Prognostic impact of TA-DCs (by in situ or flow cytometry assays.
| Marker/Population | Prognostic Impact | Histology | Reference |
|---|---|---|---|
| CD1a | Positive | Breast | [117] |
| [120] | |||
| [121] | |||
| Head and Neck | [165] | ||
| [166] | |||
| Lung | [167] | ||
| Melanoma | [130] | ||
| Negative | Osteosarcoma | [168] | |
| Biliar tracts | [169] | ||
| Colon | [125] | ||
| None | Breast | [122] | |
| Kidney | [134] | ||
| [135] | |||
| [137] | |||
| DC-LAMP | Positive | Melanoma | [130] |
| [129] | |||
| Lung | [170] | ||
| [171] | |||
| [127] | |||
| Ovary | [172] | ||
| Breast | [123] | ||
| Negative | Colon | [125] | |
| Gastric | [173] | ||
| None | Melanoma | [174] | |
| Breast | [122] | ||
| CD83 | Positive | Breast | [120] |
| Lung | [175] | ||
| Colon | [176] | ||
| Kidney | [177] | ||
| Negative | Kidney | [135] | |
| Kidney | [134] | ||
| [178] | |||
| cDC2 (BDCA1) | Negative | Lung | [145] |
| pDC (BDCA2, CD123) | Positive | Breast | [179] |
| Negative | Breast | [122] | |
| [44] | |||
| Ovary | [131] | ||
| [142] | |||
| Head and Neck | [180] | ||
| [181] | |||
| Melanoma | [174] | ||
| [146] | |||
| None | Melanoma | [128] |
TA-DCs: tumor-associated dendritic cells; cDC2: conventional dendritic cell type 2; pDC: plasmacytoid dendritic cells.